Kevin T. McVary, MD, FACS, Author at Grand Rounds in Urology

Kevin T. McVary, MD, FACS

Loyola University Chicago Stritch School of Medicine

Chicago, Illinois

Dr. Kevin T. McVary received his MD from Northwestern Medical School. He joined the faculty at Northwestern Memorial Hospital and was a Professor of Urology at Northwestern University Feinberg School of Medicine for 23 years. He served as the Director of the Center for Sexual Health at Northwestern Memorial Hospital and was Director of the Andrology Fellowship Program at Northwestern Memorial Hospital. In 2013, he joined the faculty of the Southern Illinois University School of Medicine in Springfield, Illinois, his hometown. He currently serves as Chair of the Division of Urology and Professor of Urology there.

Dr. McVary’s primary clinical areas of interest include prostate cancer and BPH, as well as the evaluation and treatment of sexual dysfunction. Dr. McVary has had extensive experience conducting clinical trials for the National Institutes of Health as well as numerous private and industry foundations.

Dr. McVary is the Chairman of the AUA’s BPH Clinical Guidelines Committee, the Co-Chair of the International Consultation on Male LUTS, and the Associate Editor of the Journal of Urology. He is also Chairman of the Special Emphasis Urology Study Section for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), as well as Co-Chairman of the Clinical Section of the NIDDK Strategic Pathway for Prostate Basic and Clinical Science. He also served on the American Board of Urology Exam Committee for four years. He was named a Sommer Lecturer at the University of Oregon in 2008.

Disclosures:

Talks by Kevin T. McVary, MD, FACS

Optilume® BPH Catheter System: Optilume® Care Pathway and Treatment Options

Posted by Kevin T. McVary, MD, FACS | Jul 2024

E. David Crawford, MD, Stephen Kaplan, MD, and Kevin T. McVary, MD, FACS, explore the utility of the Optilume® BPH Catheter System, a novel minimally-invasive surgical therapy (MIST). This is the second in a series supported by Laborie.

Dr. McVary begins with an overview of the current BPH market, diagnostic, and treatment algorithms and pharmaceutical/surgical treatment pathways. He illustrates the growing population of men with BPH who are underserved by pharmaceuticals, and those who are concerned about long-term effects of medication on their sexual function. Additionally, he discusses the dangers of delaying surgical management when it is indicated.

Dr. Kaplan then compares the function and outcomes of the Optilume® BPH Catheter System to those of current MIST and invasive surgeries. With an emphasis on the preservation of sexual function and low intraoperative risk, Dr. Kaplan and Dr. McVary discuss the clinical data, their experience with using the Optilume® BPH Catheter System, and their expectations for real-world data.

To see the Thought Leader Q&A session on this topic, click here [link to Q+A on GRU]. To see the first part of this series, click here. For more informational content on the latest developments on men’s health topics like BPH, please visit our Men’s Health Next-Generation Learning Center.

Optilume® BPH Catheter System: Optilume® Care Pathway and Treatment Options – Q&A Session

Posted by Kevin T. McVary, MD, FACS | Jul 2024

E. David Crawford, MD, Stephen Kaplan, MD, and Kevin T. McVary, MD, FACS, continue their discussion of the utility of the Optilume® BPH Catheter System in this Q&A session.

To see the main discussion on this topic, click here. This is the second in a series supported by Laborie. To see the first part of this series, click here. For more informational content on the latest developments on men’s health topics like BPH, please visit our Men’s Health Next-Generation Learning Center.

Management of Nocturia: An Unmet Need in LUTS

Posted by Kevin T. McVary, MD, FACS | Jun 2018

Kevin T. McVary, MD, illustrates that while nocturia is the leading lower urinary tract symptom (LUTS) complaint that prompts men to seek out urological care, the condition persists without improvement in 50% of patients, even after treatment. Therefore, there is a significant unmet need in nocturia management practices. He discusses the condition’s financial and quality of life (QOL) burdens, its multifactorial etiology, and his perspective on treatment approaches.